Neurodegeneration in ataxia telangiectasia: What is new? What is evident?

Neuropediatrics

Volumn 43, Issue 3, 2012, Pages 119-129

  Hoche, Franziska ^a   Seidel, Kay ^a   Theis, Marius ^a   Vlaho, Stefan ^a   Schubert, Ralf ^a   Zielen, Stefan ^a   Kieslich, Matthias ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Ataxia telangiectasia; Neurodegeneration; Neurological symptoms; Pathoanatomy; Treatment options

Indexed keywords

ACETYLCYSTEINE; ALPHA FETOPROTEIN; ALPHA TOCOPHEROL; ATM PROTEIN; BACLOFEN; CARCINOEMBRYONIC ANTIGEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CYANOCOBALAMIN; CYTOCHROME P450 REDUCTASE; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MEMANTINE; MITOGEN ACTIVATED PROTEIN KINASE 3; ONDANSETRON; PRIMIDONE; PROTEIN P53; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ASSISTED VENTILATION; ATAXIA TELANGIECTASIA; BRAIN STEM; BREAST CANCER; CANCER RISK; CELL CYCLE CHECKPOINT; CEREBELLUM; CEREBRAL TREMOR; CHROMOSOMAL INSTABILITY; CHROMOSOME ANALYSIS; COGNITION; DIENCEPHALON; DIET THERAPY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EXTRAPYRAMIDAL SYSTEM; GASTROSTOMY; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HOMEOSTASIS; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSIS; PHYSIOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SPEECH THERAPY; TREMOR; VESTIBULAR NYSTAGMUS; VITAMIN SUPPLEMENTATION;

ATAXIA TELANGIECTASIA; BRAIN; CELL CYCLE PROTEINS; HUMANS; NERVE DEGENERATION; NEURONS; TUMOR SUPPRESSOR PROTEINS;

EID: 84862755924     PISSN: 0174304X     EISSN: 14391899     Source Type: Journal    
DOI: 10.1055/s-0032-1313915     Document Type: Review

References (104)

1. Chun HH, Gatti RA. Ataxia-telangiectasia, an evolving phenotype. DNA Repair (Amst) 2004;3(8-9):1187-1196
2. Sedgwick RP, Boder E. Ataxia-telangiectasia. In: de Jong JMJV, ed. Hereditary Neuropathies and Spinocerebellar Atrophies. Vol 16, Handbook of Clinical Neurology. Amsterdam: Elsevier; 1991:347-423
3. Erichsen AK, Koht J, Stray-Pedersen A, Abdelnoor M, Tallaksen CM. Prevalence of hereditary ataxia and spastic paraplegia in southeast Norway: a population-based study. Brain 2009;132(Pt 6):1577-1588
4. Moin M, Aghamohammadi A, Kouhi A, et al. Ataxia-telangiectasia in Iran: clinical and laboratory features of 104 patients. Pediatr Neurol 2007;37(1):21-28
5. Morio T, Takahashi N, Watanabe F, et al. Phenotypic variations between affected siblings with ataxia-telangiectasia: ataxia-telangiectasia in Japan. Int J Hematol 2009;90(4):455-462
6. Swift M, Morrell D, Cromartie E, Chamberlin AR, Skolnick MH, Bishop DT. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet 1986;39(5):573-583
7. Telatar M, Teraoka S, Wang Z, et al. Ataxia-telangiectasia: identification and detection of founder-effect mutations in the ATM gene in ethnic populations. Am J Hum Genet 1998;62(1):86-97
8. Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987;316(21):1289-1294
9. Gatti RA, Berkel I, Boder E, et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22-23. Nature 1988;336(6199):577-580
10. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995;268(5218):1749-1753
11. Becker-Catania SG, Chen G, Hwang MJ, et al. Ataxia-telangiectasia: phenotype/genotype studies of ATM protein expression, mutations, and radiosensitivity. Mol Genet Metab 2000;70(2):122-133
12. Verhagen MM, Last JI, Hogervorst FB, et al. Presence of ATM protein and residual kinase activity correlates with the phenotype in ataxia-telangiectasia: a genotype-phenotype study. Hum Mutat 2012;33:561-571 Epub 2012 Jan 25. DOI: 10.1002/humu.22016
13. Gilad S, Chessa L, Khosravi R, et al. Genotype-phenotype relationships in ataxia-telangiectasia and variants. Am J Hum Genet 1998;62(3):551-561
14. Khanna KK, Lavin MF, Jackson SP, Mulhern TD. ATM, a central controller of cellular responses to DNA damage. Cell Death Differ 2001;8(11):1052-1065
15. Akyüz N, Boehden GS, Süsse S, et al. DNA substrate dependence of p53-mediated regulation of double-strand break repair. Mol Cell Biol 2002;22(17):6306-6317
16. Kruman II, Wersto RP, Cardozo-Pelaez F, et al. Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron 2004;41(4):549-561
17. Lee Y, McKinnon PJ. Responding to DNA double strand breaks in the nervous system. Neuroscience 2007;145(4):1365-1374
18. Rolig RL, McKinnon PJ. Linking DNA damage and neurodegeneration. Trends Neurosci 2000;23(9):417-424
19. Kastan MB, Zhan Q, el-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992;71(4):587-597
20. Barlow C, Hirotsune S, Paylor R, et al. ATM-deficient mice: a paradigm of ataxia telangiectasia. Cell 1996;86(1):159-171
21. Herzog KH, Chong MJ, Kapsetaki M, Morgan JI, McKinnon PJ. Requirement for ATM in ionizing radiation-induced cell death in the developing central nervous system. Science 1998;280(5366):1089-1091
22. Metcalfe JA, Parkhill J, Campbell L, et al. Accelerated telomere shortening in ataxia telangiectasia. Nat Genet 1996;13(3):350-353
23. Morgan SE, Lovly C, Pandita TK, Shiloh Y, Kastan MB. Fragments of ATM which have dominant-negative or complementing activity. Mol Cell Biol 1997;17(4):2020-2029
24. Smilenov LB, Morgan SE, Mellado W, Sawant SG, Kastan MB, Pandita TK. Influence of ATM function on telomere metabolism. Oncogene 1997;15(22):2659-2665
25. Reichenbach J, Schubert R, Schwan C, Müller K, Böhles HJ, Zielen S. Anti-oxidative capacity in patients with ataxia telangiectasia. Clin Exp Immunol 1999;117(3):535-539
26. Reichenbach J, Schubert R, Schindler D, Müller K, Böhles HJ, Zielen S. Elevated oxidative stress in patients with ataxia telangiectasia. Antioxid Redox Signal 2002;4(3):465-469
27. Kamsler A, Daily D, Hochman A, et al. Increased oxidative stress in ataxia telangiectasia evidenced by alterations in redox state of brains from ATM-deficient mice. Cancer Res 2001;61(5):1849-1854
28. Stern N, Hochman A, Zemach N, et al. Accumulation of DNA damage and reduced levels of nicotine adenine dinucleotide in the brains of ATM-deficient mice. J Biol Chem 2002;277(1):602-608
29. Liu N, Stoica G, Yan M, et al. ATM deficiency induces oxidative stress and endoplasmic reticulum stress in astrocytes. Lab Invest 2005;85(12):1471-1480
30. Reliene R, Schiestl RH. Antioxidant N-acetyl cysteine reduces incidence and multiplicity of lymphoma in ATM deficient mice. DNA Repair (Amst) 2006;5(7):852-859
31. Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT. ATM activation by oxidative stress. Science 2010;330(6003):517-521
32. Ambrose M, Goldstine JV, Gatti RA. Intrinsic mitochondrial dysfunction in ATM-deficient lymphoblastoid cells. Hum Mol Genet 2007;16(18):2154-2164
33. Eaton JS, Lin ZP, Sartorelli AC, Bonawitz ND, Shadel GS. Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis. J Clin Invest 2007;117(9):2723-2734
34. Fu X, Wan S, Lyu YL, Liu LF, Qi H. Etoposide induces ATM-dependent mitochondrial biogenesis through AMPK activation. PLoS One 2008;3(4):e2009
35. Grillari J, Grillari-Voglauer R, Jansen-Dürr P. Post-translational modification of cellular proteins by ubiquitin and ubiquitin-like molecules: role in cellular senescence and aging. Adv Exp Med Biol 2010;694:172-196
36. Wood LM, Sankar S, Reed RE, et al. A novel role for ATM in regulating proteasome-mediated protein degradation through suppression of the ISG15 conjugation pathway. PLoS One 2011;6(1):e16422
37. Desai SD, Haas AL, Wood LM, et al. Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. Cancer Res 2006;66(2):921-928
38. Eilam R, Peter Y, Groner Y, Segal M. Late degeneration of nigrostriatal neurons in ATM-/- mice. Neuroscience 2003;121(1):83-98
39. Agamanolis DP, Greenstein JI. Ataxia-telangiectasia. Report of a case with Lewy bodies and vascular abnormalities within cerebral tissue. J Neuropathol Exp Neurol 1979;38(5):475-489
40. Serra HG, Duvick L, Zu T, et al. RORalpha-mediated Purkinje cell development determines disease severity in adult SCA1 mice. Cell 2006;127(4):697-708
41. Allen DM, van Praag H, Ray J, et al. Ataxia telangiectasia mutated is essential during adult neurogenesis. Genes Dev 2001;15(5):554-566
42. Taylor AMR, Harnden DG, Arlett CF, et al. Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity. Nature 1975;258(5534):427-429
43. Lu S, Shen KC, Wang Y, Brooks SC, Wang YA. Impaired hepatocyte survival and liver regeneration in ATM-deficient mice. Hum Mol Genet 2005;14(20):3019- 3025
44. Cabana MD, Crawford TO, Winkelstein JA, Christensen JR, Lederman HM. Consequences of the delayed diagnosis of ataxia-telangiectasia. Pediatrics 1998;102(1 Pt 1):98-100
45. Shaikh AG, Marti S, Tarnutzer AA, et al. Ataxia telangiectasia: a "diseasemodel" to understand the cerebellar control of vestibular reflexes. J Neurophysiol 2011;105(6):3034-3041
46. Shaikh AG, Marti S, Tarnutzer AA, et al. Gaze fixation deficits and their implication in ataxia-telangiectasia. J Neurol Neurosurg Psychiatry 2009;80(8):858-864
47. Nissenkorn A, Levi Y, Vilozni D, et al. Neurologic presentation in childrenwitch ataxia-telangiectasia: is small head circumference a hallmark of the disease? J Pediatr 2011;159(3):466-471.e1
48. Crawford TO, Skolasky RL, Fernandez R, Rosquist KJ, Lederman HM. Survival probability in ataxia telangiectasia. Arch Dis Child 2006;91(7):610-611
49. Micol R, Ben Slama L, Suarez F, et al. Morbidity and mortality from ataxia-telangiectasia are associatedwith ATM genotype. J Allergy Clin Immunol 2011;128:382-389.e1
50. Lefton-Greif MA, Crawford TO, McGrath-Morrow S, Carson KA, Lederman HM. Safety and caregiver satisfaction with gastrostomy in patients with ataxia telangiectasia. Orphanet J Rare Dis 2011;6:23
51. McGrath-Morrow SA, Gower WA, Rothblum-Oviatt C, et al. Evaluation and management of pulmonary disease in ataxia-telangiectasia. Pediatr Pulmonol 2010;45(9):847-859
52. Taylor AM, Byrd PJ. Molecular pathology of ataxia telangiectasia. J Clin Pathol 2005;58(10):1009-1015
53. Alterman N, Fattal-Valevski A, Moyal L, et al. Ataxia-telangiectasia: mild neurological presentation despite null ATM mutation and severe cellular phenotype. Am J Med Genet A 2007;143A(16):1827-1834
54. Güngör T, Bühring I, Cremer R, Gartenschläger M, Zielen S. [Pathogenesis, diagnosis, clinical and therapeutic aspects of ataxia telangiectasia]. [Article in German] Klin Padiatr 1997;209(5):328-335
55. Wu JT, Knight JA. Serum AFP levels in normal infants: their clinical and physiological significance. In: Mzejewski GJ, Porter IH, eds. Alpha-Fetoprotein and Congenital Disorders. New York, NY: Academic Press, Inc.; 1985:111-123
56. Waldmann TA, Mcintire KR. Serum alpha-fetopretein levels in patients with ataxia-telangiectasia. Lancet 1972;300(7787):1112-1115
57. Kieslich M, Weidauer S, Boda V, et al. Kranielle kernspintomographische Befunde bei Ataxia teleangiectasia. In: Steinlin M, Kaufmann F, Fuhrer K, Strozzi S, eds. Aktuelle Neuropädiatrie 2004. Nürnberg: Novartis Pharma Verlag; 2005:136-139 [Article in German]
58. Schroeder SA, Swift M, Sandoval C, Langston C. Interstitial lung disease in patients with ataxia-telangiectasia. Pediatr Pulmonol 2005;39(6):537-543
59. Sandoval C, Swift M. Treatment of lymphoid malignancies in patients with ataxia-telangiectasia. Med Pediatr Oncol 1998;31(6):491-497
60. Verhagen MM, Abdo WF, Willemsen MA, et al. Clinical spectrum of ataxia-telangiectasia in adulthood. Neurology 2009;73(6):430-437
61. Aguilar MJ, Kamoshita S, Landing BH, Boder E, Sedgwick RP. Pathological observations in ataxia-telangiectasia. A report of five cases. J Neuropathol Exp Neurol 1968;27(4):659-676
62. Klockgether T, Schroth G, Diener HC, Dichgans J. Idiopathic cerebellar ataxia of late onset: natural history and MRI morphology. J Neurol Neurosurg Psychiatry 1990;53(4):297-305
63. Schmahmann JD, Gardner R, MacMore J, Vangel MG. Development of a brief ataxia rating scale (BARS) based on a modified form of the ICARS. Mov Disord 2009;24(12):1820-1828
64. Schmitz-Hübsch T, du Montcel ST, Baliko L, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 2006;66(11):1717-1720
65. Crawford TO, Mandir AS, Lefton-Greif MA, et al. Quantitative neurologic assessment of ataxia-telangiectasia. Neurology 2000;54(7):1505-1509
66. Verhagen MM, Martin JJ, van Deuren M, Ceuterick-de Groote C, Weemaes CM, Kremer BH, et al. Neuropathology in classical and variant ataxia-telangiectasia. Neuropathology; 2011 Oct 24; [Epub ahead of print]
67. Barzilai A. The neuro-glial-vascular interrelations in genomic instability symptoms. Mech Ageing Dev 2011;132(8-9):395-404
68. Schneider JG, Finck BN, Ren J, et al. ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab 2006;4(5):377-389
69. Solitare GB. Louis-Bar's syndrome (ataxia-telangiectasia). Anatomic considerations with emphasis on neuropathologic observations. Neurology 1968;18(12):1180-1186
70. Steffen A, Ortfeld S, Schönweiler R. Drooling bei neuropädiatrischen Patienten - ein Update. Klin Padiatr 2011;223(1):5-9 (article in German)
71. Koepp M, Schelosky L, Cordes I, Cordes M, Poewe W. Dystonia in ataxia telangiectasia: report of a case with putaminal lesions and decreased striatal [123I]iodobenzamide binding. Mov Disord 1994;9(4):455-459
72. Habek M, Brinar VV, Rados M, Zadro I, Zarković K. Brain MRI abnormalities in ataxia-telangiectasia. Neurologist 2008;14(3):192-195
73. Kieslich M, Hoche F, Reichenbach J, et al. Extracerebellar MRI-lesions in ataxia telangiectasia go along with deficiency of the GH/IGF-1 axis,markedly reduced body weight, high ataxia scores and advanced age. Cerebellum 2010;9(2):190-197
74. Isgaard J, Aberg D, Nilsson M. Protective and regenerative effects of the GH/IGF-I axis on the brain. Minerva Endocrinol 2007;32(2):103-113
75. Lefton-Greif MA, Crawford TO, Winkelstein JA, et al. Oropharyngeal dysphagia and aspiration in patients with ataxia-telangiectasia. J Pediatr 2000;136(2):225-231
76. Scarpini C, Mondelli M, Guazzi GC, Federico A. Ataxia-telangiectasia: somatosensory, brainstem auditory and motor evoked potentials in six patients. Dev Med Child Neurol 1996;38(1):65-73
77. Taylor MJ, Logan WJ. Multimodal electrophysiological assessment of ataxia telangiectasia. Can J Neurol Sci 1983;10(4):261-265
78. Verhagen MMM, van Alfen N, Pillen S, et al. Neuromuscular abnormalities in ataxia telangiectasia: a clinical, electrophysiological and muscle ultrasound study. Neuropediatrics 2007;38(3):117-121
79. Wong V, Yu YL, Chan-Lui WY, Woo E, Yeung CY. Ataxia telangiectasia in Chinese children. A clinical and electrophysiological study. Clin Neurol Neurosurg 1987;89(3):137-144
80. Farina L, Uggetti C, Ottolini A, et al. Ataxia-telangiectasia: MR and CT findings. J Comput Assist Tomogr 1994;18(5):724-727
81. Alfonsi E, Merlo IM, Monafo V, et al. Electrophysiologic study of central motor pathways in ataxia-telangiectasia. J Child Neurol 1997;12(5):327-331
82. Malandrini A, Guazzi GC, Alessandrini C, Federico A. Peripheral nerve involvement in ataxia telangiectasia: histological and ultrastructural studies of peroneal nerve biopsy in two cases. Clin Neuropathol 1990;9(3):109-114
83. Mostofsky SH, Kunze JC, Cutting LE, Lederman HM, Denckla MB. Judgment of duration in individuals with ataxia-telangiectasia. Dev Neuropsychol 2000;17(1):63-74
84. Vinck A, Verhagen MM, Gerven M, et al. Cognitive and speech-language performance in childrenwith ataxia telangiectasia. Dev Neurorehabil 2011;14(5):315-322
85. Levisohn L, Cronin-Golomb A, Schmahmann JD. Neuropsychological consequences of cerebellar tumour resection in children: cerebellar cognitive affective syndrome in a paediatric population. Brain 2000;123(Pt 5):1041-1050
86. Schmahmann JD, Sherman JC. The cerebellar cognitive affective syndrome. Brain 1998;121(Pt 4):561-579
87. Schmahmann JD. The role of the cerebellum in cognition and emotion: personal reflections since 1982 on the dysmetria of thought hypothesis, and its historical evolution from theory to therapy. Neuropsychol Rev 2010;20(3):236-260
88. Schmahmann JD. An emerging concept. The cerebellar contribution to higher function. Arch Neurol 1991;48(11):1178-1187
89. Schmahmann JD. From movement to thought: anatomic substrates of the cerebellar contribution to cognitive processing. Hum Brain Mapp 1996;4(3):174-198
90. Timmann D, Daum I. Cerebellar contributions to cognitive functions: a progress report after two decades of research. Cerebellum 2007;6(3):159-162
91. Lavin MF, Gueven N, Bottle S, Gatti RA. Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia. Br Med Bull 2007;81-82:129-147
92. Davies EG. Update on the management of the immunodeficiency in ataxia-telangiectasia. Expert Rev Clin Immunol 2009;5(5):565-575
93. Mitra A, Gooi J, Darling J, Newton-Bishop JA. Infliximab in the treatment of a child with cutaneous granulomas associated with ataxia telangiectasia. J Am Acad Dermatol 2011;65(3):676-677
94. Zielen S, Schubert R. Workshop report: European workshop on ataxia-telangiectasia, Frankfurt, 2011. J Neurogenet 2011;25(3):78-81
95. Marmolino D, Manto M. Past, present and future therapeutics for cerebellar ataxias. Curr Neuropharmacol 2010;8(1):41-61
96. Perlman SL. Cerebellar ataxia. Curr Treat Options Neurol 2000;2(3):215-224
97. Perlman S, Becker-Catania S, Gatti RA. Ataxia-telangiectasia: diagnosis and treatment. Semin Pediatr Neurol 2003;10(3):173-182
98. Buoni S, Zannolli R, Sorrentino L, Fois A. Betamethasone and improvement of neurological symptoms in ataxia-telangiectasia. Arch Neurol 2006;63(10):1479-1482
99. Erker L, Schubert R, Elchuri S, et al. Effect of the reduction of superoxide dismutase 1 and 2 or treatment with alpha-tocopherol on tumorigenesis in ATM-deficient mice. Free Radic Biol Med 2006;41(4):590-600
100. Schubert R, Reichenbach J, Zielen S. Growth factor deficiency in patients with ataxia telangiectasia. Clin Exp Immunol 2005;140(3):517-519
101. Schubert R, Schmitz N, Pietzner J, et al. Growth hormone supplementation increased latency to tumourigenesis in ATM-deficient mice. Growth Factors 2009;27(5):265-273
102. Du L, Pollard JM, Gatti RA. Correction of prototypic ATM splicing mutations and aberrant ATM function with antisense morpholino oligonucleotides. Proc Natl Acad Sci U S A 2007;104(14):6007-6012
103. Amariglio N, Hirshberg A, Scheithauer BW, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 2009;6(2):e1000029
104. Marshall C. Life through the eyes of a disabled person. Arch Dis Child 2004;89(9):887